Tokyo, Sept. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058428) titled 'Additive effect of P2X3 inhibitor, gefapixant, on azelastin for refractory atopic cough' on Sept. 30.
Study Type:
Observational
Primary Sponsor:
Institute - Respiratory and Allergy Medicine, Kansai Medial University
Condition:
Condition - Atopic cough
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - A retrospective clinical study will be conducted to evaluate the efficacy of gefapixant, a P2X3 inhibitor for the new treatment of chronic cough, in patients with refractory atopic cough in real clinical practice.
Basic objectives2 - Efficacy
Eligibility:
Age-lower li...